本文へ

当サイトでは、利用測定やトラフィック分析を目的として、クッキー(Cookie)を利用しています。
「同意する」ボタンや本サイトをクリックすることで、クッキーの利用に同意いただいたことになります。
詳しくはプライバシーポリシー別ウィンドウで開くをご覧ください。

同意する

ATLAS Asia Clinical Trials Network for Cancers Project
企業の方へ
Language
検索
menu
  1. ホーム
  2. 各室員・研究員プロフィール
  3. Yung-Yeh Su

Yung-Yeh Su , MD, PhD

職名（所属）
Assistant Investigator and Attending Physician
施設名

National Institute of Cancer Research

専門治療 Hepatobiliary and pancreatic cancer
Yung-Yeh Su

Dr. Yung-Yeh Su’s Story

Dr. Su is a clinician-scientist dedicated to advancing precision oncology for hepatobiliary and pancreatic cancers through investigator-initiated trials and translational research. His work integrates clinical data with next-generation sequencing to dissect tumor heterogeneity. In pancreatic cancer, he advanced endoscopic biopsy techniques (Gastrointestinal Endoscopy, 2023), enabling landmark single-cell sequencing studies (Molecular Cancer, 2025), and identified key germline and pharmacogenomic markers to personalize therapy (Clin Cancer Res, 2026). In hepatocellular carcinoma, his research has been pivotal in defining immunotherapy response mechanisms, including pathological response criteria (Lancet Oncology, 2024), features of durable benefit (Journal of Clinical Oncology, 2024), and the role of B-cells in treatment efficacy (Journal of Hepatology, 2025).

With over 40 peer-reviewed articles, Dr. Su’s research excellence is recognized by the JSMO Young Investigator Award for four consecutive years (2022–2025) and the 2024 Taiwan Oncology Society Young Investigator Paper Award.

 

Research Interest

Tumor Heterogeneity, Next-Generation Sequencing & scRNA-seq, Translational Research & Immunotherapy Response, Precision Oncology in GI Cancers

Qualifications, certified physicians, medical specialists, etc.

Board of Medical Oncology

Specialized field

Clinical trials and translational research in hepatobiliary and pancreatic cancers.

Professional Experience

  • Assistant Investigator and Attending Physician, National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
  • Adjunct Attending physician, Department of Internal Medicine, Kaohsiung Medical University Hospital and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan
  • Adjunct Attending physician, Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan
  • Visiting Scholar, Stanford Cancer Center, California, USA.
  • Fellow, Division of Medical Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
PAGE TOP